SCHEMBL3370902

SCHEMBL3370902

O=c1ccn(-c2ccc([N+](=O)[O-])cc2)c(=O)[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 3/20 0.58
DDB1 Q16531 1/20 0.58
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 3/20 0.45
PLEC Q15149 1/20 0.45
SIRT6 Q8N6T7 2/20 0.44
SCN2A Q99250 1/20 0.44
ADRB1 P08588 1/20 0.44
MAPT P10636 7/20 0.43
MCL1 Q07820 2/20 0.43
TP53 P04637 1/20 0.43
RECQL P46063 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23296154 0.82 DDB1 (0.57) CRBNDDB1MEN1KMT2APOLB
SCHEMBL23296112 0.76 ATM (0.47) CRBNDDB1MEN1KMT2APOLB
SCHEMBL30955769 0.76 POLB (0.44) MEN1KMT2APOLBPLECSIRT6
SCHEMBL16167009 0.76 MAPT (0.43) MEN1KMT2APOLBPLECSIRT6
SCHEMBL23296136 0.74 DBH (0.54) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL5575269 0.74 PARL (0.49) CRBNRAB9AALDH1A1
SCHEMBL23296109 0.74 ACHE (0.46) MEN1KMT2APOLBPLECSIRT6
SCHEMBL21995599 0.74 CRBN (0.66) CRBNDDB1KMT2APOLBHTT
SCHEMBL23120610 0.74 CRBN (0.66) CRBNDDB1KMT2AL3MBTL1ALDH1A1
SCHEMBL25207533 0.74 CRBN (0.66) CRBNDDB1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025108404-A1 HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND USE THEREOF 广东东阳光药业股份有限公司 2025-05-30 WO disclosed
CN-120025326-A Heterocyclic compound of bifunctional chimera for targeting and degrading androgen receptor and application thereof 广东东阳光药业股份有限公司 2025-05-23 CN disclosed
EP-1636216-B1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-07-21 EP disclosed
US-7741341-B2 Benzimidazole-derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-22 US disclosed
EP-1636216-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-22 EP disclosed
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-13 US disclosed
WO-2004101553-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO disclosed
US-4931444-A FOR LEUKOTRIENE-MEDIATED DISEASES AND DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 1990-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors F12, F11, F5 CRBN 2969/4885DDB1 4449/4885MEN1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.